Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

2014 ACR/ARHP Annual Meeting: Evelyn V. Hess Award Presentation

Staff  |  Issue: February 2015  |  February 1, 2015

—Dr. Salmon

“But there was more to know. When I tell a woman that she has lupus, one of her first questions is, ‘Doctor, will I be able to have children?’ For many years, we thought that pregnancy caused lupus to flare and should be avoided. This recommendation, however, was not based on strong data, and we knew that some women with lupus had uncomplicated pregnancies, while others had miscarriages or preeclampsia.

“To understand the mechanism of pregnancy failure in lupus, we developed a model of the disease in mice. It was a new area for me, and, perhaps because I approached it without a bias, I could test and prove a hypothesis that challenged long-held dogma. We showed that inflammation, particularly complement activation (and not thrombosis), was a key mediator of poor pregnancy outcome in APL-treated mice. We also found that drugs that block complement could prevent fetal death, growth restriction and preeclampsia in mice.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“But, of course, the ultimate goal of the mice experiments was to help patients. The first step in applying our findings to lupus patients was to identify those destined for poor pregnancy outcome. Lupus is not a common disease. Pregnant lupus patients are less common, and those willing to participate in studies, even harder to come by. Moreover, we had to convince the NIH that a large, multicenter study, expensive study was likely to yield markers that predicted outcome. Here, I was fortunate that foundations (Alliance for Lupus Research) and individual donors—most generously Kit and Arnie Snider who funded the MKCLC at HSS—supported preliminary studies that made possible a compelling proposal, one that was awarded federal funding. I must thank Susana Serrate-Sztein of NIAMS, a dedicated and visionary steward of the public trust, for believing in us and helping us gain permission to submit what some could have been construed as an audacious proposal to NIAMS.

“The PROMISSE study has exceeded my expectations for success in enrolling patients and generating important new information. Over 11 years of funding, $14 million all told, we studied 755 pregnant patients monthly. They were recruited at eight centers in the U.S. and Canada, and from them, we collected nearly a quarter-million samples. Ours is the largest prospective study of lupus pregnancies.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“PROMISSE taught us that pregnancy in lupus patients with quiescent disease is safe. This reassuring finding will enable physicians to counsel patients about how to time pregnancy. PROMISSE also allowed us to identify biomarkers that, early in pregnancy, predict life-threatening complications for mother and fetus.

Page: 1 2 3 4 5 6 7 8 9 | Single Page
Share: 

Filed under:Meeting ReportsProfilesResearch Rheum Tagged with:2014 ACR/ARHP Annual MeetingAC&RAssociation of Rheumatology Professionals (ARP)AwardsLupus FoundationResearchrheumatologySalmonTsokos

Related Articles

    It’s All About the Patient

    October 7, 2011

    Trailblazer Evelyn V. Hess combines science and patient care

    Rheum After 5: Dr. George Tsokos Shares His Love & Friendship with a Cat

    October 19, 2020

    George C. Tsokos, MD, professor of medicine at Harvard Medical School and chief of the Division of Rheumatology, Beth Israel Deaconess Medical Center, both in Boston, doesn’t recall the moment he first became infatuated with Little, a 12-year-old Siamese cat. Dr. Tsokos doesn’t even own Little. Not that anyone can truly own any living creature….

    A Better Family Plan

    October 1, 2007

    How to minimize the risks of pregnancy for women with SLE

    Protein Phosphatase 2A and Regulatory T Cell Function Researched

    June 13, 2016

    The serine-threonine protein phosphatase 2A (PP2A) enzyme is critical for regulatory T cells to function—without it, they don’t have the ability to suppress effector T cells and can’t protect against autoimmunity, according to new research published in Nature Immunology. Researchers found that conditional knockout mice—in which PP2A expression is knocked out only in regulatory T cells—developed…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences